Chroma Medicine Stock

chromamedicine.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $262MM

Chroma Medicine leverages genomic medicine to develop therapeutics able to control gene expression. With the ability to target parts of the genome, the goal is relief for patients suffering from severe illnesses. Chroma Medicine was founded in 2021 by Angelo Lombardo Ph.D., Luigi Naldini Ph.D., David Liu Ph.D., and Jonathan Weissman Ph.D. and is headquartered in Boston, MA.

Register To Buy and Sell Shares

For more details on financing and valuation for Chroma Medicine, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Chroma Medicine’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Chroma Medicine.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Vic Myer Ph.D
Chief Scientific Officer & President
Brett Kaplan MD
Chief Financial and Strategy Officer & Chief Corporate Development Officer

Board Members

Bihua Chen
Cormorant Asset Management
George Golumbeski Ph.D
ARCH Venture Partners
John Maraganore Ph.D
ARCH Venture Partners
Thomas Cahill Ph.D
Newpath Partners

Frequently Asked Questions About Chroma Medicine’s Stock

plusminus
Can you buy Chroma Medicine’s stock?
Chroma Medicine is not publicly traded on NYSE or NASDAQ in the U.S. To buy Chroma Medicine’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Chroma Medicine’s stock?
Yes, you can sell stock of a private company like Chroma Medicine. Forge can help you sell your Chroma Medicine stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Chroma Medicine’s stock price?
Chroma Medicine is a privately held company and therefore does not have a public stock price. However, you may access Chroma Medicine’s private market stock price with Forge Data.
plusminus
What is Chroma Medicine’s stock ticker symbol?
Chroma Medicine does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Chroma Medicine raises $135 million for its epigenetic editing therapies
Chroma's approach, known as epigenetic editing, could have broad applications for treating both rare and common diseases.
Chroma bags another 9-digit financing, taking $135M series B to bolster epigenetic-focused platform
A more cautious financing market is evidently no barrier for Chroma Medicine and its epigenetic-focused tech, with the Cambridge, Massachusetts-based biotech bagging $135 million in series B funds to build out its platform.
Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy
Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the formation of a Scientific Advisory Board (SAB) comprising renowned leaders in epigenetics, cell and gene therapy, and synthetic biology: Bradley Bernstein, M.D., Ph.D., Paula Cannon, Ph.D., Howard Chang, M.D., Ph.D., and Ahmad (Mo) Khalil, Ph.D.
Updated on: Apr 14, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.